HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Supratentorial primitive neuroectodermal tumor — Clinical Guidelines

Overview

Supratentorial primitive neuroectodermal tumors (sPNET) are aggressive, embryonal tumors arising from neural crest cells within the supratentorial region of the brain. These tumors are particularly malignant, often presenting with rapid progression and poor prognosis, especially in pediatric populations. They frequently occur in children but can also affect teenagers and young adults. Given their aggressive nature and potential for significant neurological impairment or mortality, accurate diagnosis and timely intervention are critical in day-to-day clinical practice to improve patient outcomes 1 4.

Pathophysiology

sPNETs originate from undifferentiated neural progenitor cells within the supratentorial regions, characterized by their rapid proliferation and undifferentiated cellular morphology. Molecularly, these tumors often exhibit distinct genetic alterations that differentiate them from other pediatric brain tumors like medulloblastomas. Notably, deletions in the CDKN2A locus and aberrations at chromosome regions 1p12-22.1 and 9p are frequently observed in sPNETs, contributing to uncontrolled cell proliferation and resistance to apoptosis 5. Additionally, the presence of specific molecular subtypes, such as group 3 sPNETs marked by TWIST1 and FOXJ1 expression, highlights the heterogeneity within this tumor type, influencing both pathogenesis and therapeutic response 1. The maintenance of a cancer stem cell (CSC) pool further complicates treatment, as these cells often exhibit resistance to conventional therapies, necessitating targeted approaches to eradicate the entire tumor population 1.

Epidemiology

The incidence of sPNETs is relatively low compared to other pediatric brain tumors, with an estimated annual incidence of approximately 2-3 cases per million children under 15 years of age 4. These tumors predominantly affect children, with a median age at diagnosis around 5-8 years, though they can occur in older pediatric and young adult populations. There is no significant sex predilection observed in most studies. Geographic distribution does not show marked regional variations, but specific risk factors remain largely undefined beyond the general context of pediatric brain tumors. Trends over time suggest stable incidence rates, though advancements in diagnostic techniques may influence reported frequencies 4.

Clinical Presentation

sPNETs typically present with nonspecific neurological symptoms due to their location in the supratentorial region, often leading to mass effect and increased intracranial pressure. Common clinical features include headaches, vomiting, altered mental status, and focal neurological deficits such as hemiparesis or seizures. Perifocal edema, which can be exacerbated by dysfunction of the glymphatic system, may contribute to rapid clinical deterioration and increased intracranial pressure 2. Red-flag features include rapid progression of symptoms, signs of raised intracranial pressure, and cognitive decline, necessitating urgent neuroimaging for definitive diagnosis 2 3.

Diagnosis

The diagnostic approach for sPNET involves a combination of clinical evaluation, neuroimaging, and histopathological analysis. Key steps include:

Neuroimaging: MRI is the gold standard, revealing heterogeneous masses with characteristic enhancement patterns and perifocal edema. Diffusion tensor MRI (DT-MRI) can provide additional insights into glymphatic system dysfunction, particularly useful in assessing perifocal edema 2.

Biopsy and Histopathology: Definitive diagnosis relies on stereotactic biopsy or surgical resection followed by histopathological examination. Immunohistochemical markers such as CD133, CD15, and molecular profiling for TWIST1 and FOXJ1 help subclassify the tumor into specific subtypes like group 3 sPNET 1.

Molecular Analysis: Genetic testing for deletions in CDKN2A and other genomic aberrations (e.g., 1p12-22.1, 9p) aids in confirming the diagnosis and guiding treatment strategies 5.

Specific Criteria and Tests:

MRI Findings: Heterogeneous mass with peritumoral edema, characteristic enhancement patterns.

Histopathological Criteria: Undifferentiated neuroepithelial cells, positive for markers like CD133 and CD15.

Molecular Markers: TWIST1 and FOXJ1 expression for group 3 subtype identification; CDKN2A deletions confirmed via FISH or array-CGH.

Differential Diagnosis:

- Medulloblastoma: Typically located in the posterior fossa, with different molecular profiles. - Atypical Teratoid/Rhabdoid Tumor (AT/RT): Often younger age group, distinct histological features. - High-Grade Gliomas: More common in older children, different genetic alterations.

Management

Initial Treatment

Surgical Debulking: Primary surgical resection to reduce tumor burden and alleviate symptoms caused by mass effect.

- Specifics: Aim for maximal safe resection, considering eloquent brain areas. - Monitoring: Postoperative neurological status, imaging follow-up.

Adjuvant Therapy

Cranio-Spinal Irradiation (CSI): Post-surgery, to target residual disease and prevent dissemination.

- Specifics: Total dose and fractionation protocol tailored to age and tolerance. - Monitoring: Cognitive function, endocrinological status.

Chemotherapy: Often based on regimens used for medulloblastoma, such as the Packer regimen.

- Specifics: Cisplatin, vincristine, cyclophosphamide, and doxorubicin; dosing and schedule as per institutional protocols. - Monitoring: Hematological parameters, renal function, hearing assessments.

Refractory or Recurrent Disease

Second-Line Chemotherapy: Consideration of alternative agents or targeted therapies based on molecular profiles.

- Specifics: Agents like temozolomide, or experimental targeted therapies targeting specific genetic alterations. - Monitoring: Regular imaging, biomarker assessments, and multidisciplinary tumor board reviews.

Radiation Therapy: Re-evaluation of radiation fields and doses for recurrent disease.

- Specifics: Palliative radiation for symptom control in refractory cases. - Monitoring: Neurological status, quality of life assessments.

Contraindications

Surgical Debulking: Significant comorbidities, eloquent brain involvement precluding safe resection.

Chemotherapy: Severe organ dysfunction, particularly renal and hepatic impairment.

Complications

Acute Complications: Postoperative neurological deficits, infection, hemorrhage.

- Management Triggers: Immediate neurological deterioration, fever, signs of infection.

Long-Term Complications: Cognitive impairment, endocrine dysfunction (hypopituitarism, DI), secondary malignancies.

- Management Triggers: Persistent cognitive decline, growth abnormalities, hormonal imbalances. - Referral: Endocrinology, neurorehabilitation specialists as needed.

Prognosis & Follow-Up

The prognosis for sPNET remains guarded, with overall survival rates historically low, particularly in non-pineal cases, often around 9-14% at 5 years 4. Prognostic indicators include molecular subtype, extent of resection, and response to adjuvant therapies. Recommended follow-up includes:

Neuroimaging: Regular MRI scans (every 3-6 months initially, then annually).

Endocrinological Assessments: Periodic evaluation of pituitary and hypothalamic function.

Neurological Evaluations: Regular assessments for cognitive and motor function.

Survival Rates: Tailored based on individual response and molecular profile.

Special Populations

Pediatrics: Focus on minimizing neurocognitive impact through careful surgical and radiation planning.

- Specifics: Tailored chemotherapy regimens to reduce long-term side effects.

Endocrinopathy: Increased vigilance for hypothalamic-pituitary dysfunction post-surgery and radiation.

- Specifics: Early hormonal assessments and management with hormone replacement therapy 3.

Key Recommendations

Surgical Resection: Aim for maximal safe resection to reduce tumor burden and alleviate symptoms (Evidence: Strong 1).

Cranio-Spinal Irradiation (CSI): Essential post-surgery to target residual disease (Evidence: Strong 4).

Chemotherapy: Use regimens based on medulloblastoma protocols, with close monitoring of toxicity (Evidence: Moderate 4).

Molecular Profiling: Incorporate genetic testing for CDKN2A deletions and other aberrations to guide personalized treatment (Evidence: Moderate 5).

Endocrinological Monitoring: Regular assessments for hypothalamic-pituitary dysfunction post-treatment (Evidence: Moderate 3).

Neuroimaging Follow-Up: Schedule MRI scans every 3-6 months initially, then annually to monitor for recurrence (Evidence: Moderate 2).

Consider Targeted Therapies: Evaluate second-line treatments based on molecular profiles in refractory cases (Evidence: Weak 4).

Multidisciplinary Care: Involve neurosurgery, oncology, endocrinology, and neurorehabilitation teams for comprehensive management (Evidence: Expert opinion).

Glymphatic System Assessment: Utilize DT-MRI to assess perifocal edema and glymphatic dysfunction in patients with significant peritumoral changes (Evidence: Moderate 2).

Palliative Care Integration: Early involvement of palliative care to manage symptoms and improve quality of life (Evidence: Expert opinion).

References

1 Liu Z, Zhao X, Wang Y, Mao H, Huang Y, Kogiso M et al.. A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children. Neuro-oncology 2014. link 2 Turkin AM, Melnikova-Pitskhelauri TV, Fadeeva LM, Kozlov AV, Oshorov AV, Kravchuk AD et al.. Perifocal edema and glymphatic system dysfunction: quantitative assessment based on diffusion tensor magnetic resonance imaging. Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko 2023. link 3 Babiker A, Alaqeel B, Al-Eyadhy A, Selayem NA, Alissa S, Alsofyani A et al.. Postoperative intensive care management and residual endocrinopathy of pediatric supratentorial brain tumors: a retrospective cohort study. Journal of pediatric endocrinology & metabolism : JPEM 2022. link 4 Biswas S, Burke A, Cherian S, Williams D, Nicholson J, Horan G et al.. Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation?. Pediatric blood & cancer 2009. link 5 Pfister S, Remke M, Toedt G, Werft W, Benner A, Mendrzyk F et al.. Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. Genes, chromosomes & cancer 2007. link 6 Frühwald MC, Rickert CH, O'Dorisio MS, Madsen M, Warmuth-Metz M, Khanna G et al.. Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging. Clinical cancer research : an official journal of the American Association for Cancer Research 2004. link

Supratentorial primitive neuroectodermal tumor